Litcius/Paper detail

Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant

Luca Malorni, Svitlana Tyekucheva, Florentine Hilbers, Michail Ignatiadis, Patrick Neven, Marco Colleoni, Stéphanie Henry, Alberto Ballestrero, Andrea Bonetti, Guy Jérusalem, Konstantinos Papadimitriou, Antônio Bernardo, Elena Seles, François P. Duhoux, Iain R. Macpherson, Alastair Thomson, D. M. Davies, Mattias Bergqvist, Ilenia Migliaccio, Géraldine Gebhart, Gabriele Zoppoli, Judith M. Bliss, Matteo Benelli, Amelia McCartney, Roswitha Kammler, Heidi De Swert, Barbara Ruepp, Debora Fumagalli, Rudolf Maibach, David Cameron, Sherene Loi, Martine Piccart, Meredith M. Regan

2022European Journal of Cancer24 citationsDOIOpen Access PDF

Topics & Concepts

PalbociclibFulvestrantMedicineMetastatic breast cancerInternal medicineBreast cancerOncologyCyclin-dependent kinase 4CancerClinical endpointLetrozoleEndocrinologyClinical trialEstrogen receptorCell cycleAromataseCyclin-dependent kinase 2Advanced Breast Cancer TherapiesCancer-related Molecular PathwaysHER2/EGFR in Cancer Research